Kevin Liu

Mr. Kevin Liu

Athinoula A. Martinos Center for Biomedical Imaging
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
XKXuejun Kong
Xuejun Kong
JLJun Liu
Jun Liu
Kevin LiuKevin Liu
Kevin Liu
MKMadelyn Koh
Madelyn Koh
HSHannah Sherman
Hannah Sherman
YSYiqing Song
Yiqing Song
Autism spectrum disorder (ASD) is a rapidly growing neurodevelopmental disorder. Both probiotics and oxytocin were reported to have therapeutic potential; however, the combination therapy has not yet been studied. We conducted a randomized, double-blinded, placebo-controlled, 2-stage pilot trial in 35 individuals with ASD aged 3–20 years (median = 10.30 years). Subjects were randomly assigned to receive daily Lactobacillus plantarum PS128 probiotic (6 × 1010 CFUs) or a placebo for 28 weeks; starting on week 16, both groups received oxytocin. The primary outcomes measure socio-behavioral severity using the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). The secondary outcomes include measures of the Clinical Global Impression (CGI) scale, fecal microbiome, blood serum inflammatory markers, and oxytocin. All outcomes were compared between the two groups at baseline, 16 weeks, and 28 weeks into treatment. We observed improvements in ABC and SRS scores and significant improvements in CGI-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05). A significant number of favorable gut microbiome network hubs were also identified after combination therapy (p < 0.05). The favorable social cognition response of the combination regimen is highly correlated with the abundance of the Eubacterium hallii group. Our findings suggest synergic effects between probiotics PS128 and oxytocin in ASD patients, although further investigation is warranted.

21 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
JHJie Huang
Jie Huang
JLJun Liu
Jun Liu
RTRuiyi Tian
Ruiyi Tian
Kevin LiuKevin Liu
Kevin Liu
PZPatrick Zhuang
Patrick Zhuang
XKXuejun Kong
Xuejun Kong
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with strong genetic influences. There is an increasing demand for ASD genetic testing beyond the traditionally recommended microarray and syndromic autism testing; however, the current whole genome sequencing (WGS) and whole exome sequencing (WES) methods are lacking an academic standard for WGS variant annotation, reporting, and interpretation, tailored towards patients with ASD and offer very limited interpretation for clinical significance. Using WGS data from six family trios, we demonstrate the clinical feasibility and technical implementation of an evidence-based, fully transparent bioinformatics pipeline and report framework for an ASD-focused WGS genetic report. We confirmed a portion of the key variants with Sanger sequencing and provided interpretation with consideration of patients’ clinical symptoms and detailed literature review. Furthermore, we showed that identification of the genetic contributions of ASD core symptoms and comorbidities may promote a better understanding of the ASD pathophysiology, lead to early detection of associated comorbidities, and facilitate pharmacologic intervention based on pathological pathways inferred from the genetic information. We will make the bioinformatics pipeline and interpretation framework publicly available, in an easily accessible format, after validation with a larger cohort. We hope that the present proposed protocol can serve as a starting point to invite discourse and debate to further improve approaches in WGS-based genetic consultation for patients with ASD.

5 October 2017 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
XYXiaoyu Yan
Xiaoyu Yan
PCPamela L. Clemens
Pamela L. Clemens
TPThomas Puchalski
Thomas Puchalski
SLSagar Lonial
Sagar Lonial
HLHenk Lokhorst
Henk Lokhorst
SXsteven Xu
steven Xu
Objective The aim of this study was to understand the influence of disease and patient characteristics on exposure to daratumumab, an immunoglobulin Gκ (IgGκ) monoclonal antibody, and clinical outcomes in relapsed or refractory multiple myeloma (MM). Patients and Methods Baseline myeloma type, albumin levels, renal/hepatic function, age, sex, race, weight, Eastern Cooperative Oncology Group (ECOG) status, refractory status, and number of prior therapies were evaluated using data from two clinical studies—GEN501 (N = 104) and SIRIUS (N = 124). Results Daratumumab clearance was approximately 110% higher in IgG myeloma patients than non-IgG myeloma patients, leading to significantly lower exposure in IgG myeloma patients based on maximum trough serum concentrations (p < 0.0001). However, the overall response rate was similar for IgG and non-IgG myeloma patients (odds ratio 1.08, 95% confidence interval 0.54–2.17, p = 0.82). For a given exposure, the drug effect was significantly higher (approximately two times) in IgG versus non-IgG patients (p = 0.03). The influence of other patient and disease characteristics on daratumumab exposure was minimal and no significant effect on efficacy was observed (p ≥ 0.1). The incidences of infections and overall grade 3 or higher adverse events in subpopulations were generally consistent with that of the overall population. Conclusion Due to competition with the MM-produced IgG M-protein for neonatal Fc receptor protection from clearance, IgG-based monoclonal antibodies in general may have significantly higher clearance and lower concentrations in IgG MM patients compared with non-IgG MM patients. Careful evaluation of the impact of exposure and patient and disease characteristics on safety and efficacy is warranted for all IgG-based monoclonal antibodies used in MM.


10 February 2026 in Journal of Sleep Research
Verified
Journal Article
Open access
Kevin LiuKevin Liu
Kevin Liu
BSBinbin Sun
Binbin Sun
BWBryan K. Wang
Bryan K. Wang
JCJonathan Chen
Jonathan Chen
MWMichael Brandon Westover
Michael Brandon Westover
XKXuejun Kong
Xuejun Kong
We investigated whether sleep microstructures show spatial differences in young children with autism compared with typically developing peers. 32‐channel electroencephalography (EEG) during natural sleep after 5–6 h of partial sleep deprivation was recorded from 53 children (26 with autism, 27 typically developing; 1.1–5.1 years). Quantified EEG features included spindle density, frequency, morphology, slow oscillations and the relative power of infraslow oscillations (0.005–0.03 Hz). Clinical associations were examined using the Autism Diagnostic Observation Schedule, the Childhood Autism Rating Scale and the Gesell Developmental Schedules. Children with autism showed greater modulation of spindle frequency by the phase of slow oscillations at a right frontal scalp electrode (F8). An infraslow peak slightly below 0.02 Hz was present in both groups. Although group differences in infraslow power did not remain significant after correction for multiple comparisons, infraslow power correlated positively with autism severity in males, over posterior and temporal regions. These findings indicate that sleep microstructures in early childhood reflect thalamocortical and cortical dysfunction with sex‐specific clinical associations.

3 December 2015 in Blood
Verified
Journal Article
Open access
XXXu Steven Xu
Xu Steven Xu
XYXiaoyu Yan
Xiaoyu Yan
TPThomas Puchalski
Thomas Puchalski
SLSagar Lonial
Sagar Lonial
HLHenk M. Lokhorst
Henk M. Lokhorst
PCPamela L Clemens
Pamela L Clemens
Introduction: Daratumumab is a first-in-class human anti-CD38 immunoglobulin G1 (IgG1) monoclonal antibody in clinical development for multiple myeloma (MM). Nonlinear concentration- and time-dependent pharmacokinetics was observed due to target-mediated drug disposition. Identification of an optimal dose regimen was complicated by the interactions between daratumumab pharmacokinetics and pharmacodynamics of the target (CD38) and a clinical dosing schedule with decreasing dose frequency over time. The objective of this analysis was to understand and justify the recommended dose and dosing schedule for daratumumab in MM patients from a quantitative pharmacologic perspective. Methods: Analyzed data were from a phase 1/2, 2-part study beginning with dose-escalation followed by a single-arm multiple cohort phase (GEN501, NCT00574288) and a phase 2 study that evaluated the efficacy and safety of daratumumab monotherapy (MMY2002, NCT01985126). Doses ranged from 0.01 to 24 mg/kg and dose schedules varied by cohort in these studies. We explored the exposure-response relationship for the efficacy and safety endpoints. Simulations were conducted based on a previously developed population pharmacokinetic model to understand the association between target saturation and daratumumab exposure. Results: There was a maximum effect (Emax) relationship between daratumumab exposure (ie, maximal trough concentration) and overall response rate (ORR), and between daratumumab and target saturation. The concentration associated with 90% maximal effect on ORR (ECORR90) was 274 µg/mL which is similar to the concentration providing 99% model-predicted target saturation (ECTAR99, 236 µg/mL). The 16 mg/kg dose was the lowest tested dose at which the majority (approximately 80%) of subjects achieved serum concentrations above ECORR90 and ECTAR99 thresholds after weekly administration (weekly for 8 weeks). Since the total clearance of daratumumab decreased over time, the intensive weekly dosing at the beginning of treatment was intended to overcome the high initial clearance and rapidly establish the efficacious concentration. Thereafter, every 2-week followed by every 4-week 16 mg/kg dosing intervals appeared to be adequate to saturate the target and maintain the total clearance close to the non-specific linear clearance. Although the concentration of daratumumab tended to decrease following every 2-week and every 4-week dosing intervals until reaching steady state, the reduction in concentration over time observed in the studies was not associated with either shorter duration of response or higher risk of disease progression. This result corroborates the clinical analysis which indicated the rate of subjects experiencing disease progression was consistent in the every 2-week and every 4-week dosing periods. The exposure-safety analysis demonstrated no apparent relationship between the drug exposure and infusion-related reactions, thrombocytopenia, anemia, neutropenia, or lymphopenia. Although the overall event rate of infection increased numerically with drug exposure, this trend was not observed for infections of Grade 3 or higher. The clinical data suggested that the safety profile of the 16 mg/kg dose was consistent with the total population, and there was no increasing trend noted in the overall incidence of treatment-emergent adverse events across increasing dose groups. Treatment with 16 mg/kg daratumumab weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until progression resulted in high ORRs of 29% in Study MMY2002 and 36% in Study GEN501. Conclusion: Our analysis demonstrated that the recommended dose regimen is appropriate in the relapsed or refractory MM patient population. Lowering the dose would likely result in reduced efficacy, whereas increasing the dose may not improve the benefit-risk profile. In addition, the dosing schedule rapidly establishes efficacious concentrations during the initial, intense, weekly dosing period and maintains target saturation thereafter; thus reducing the risk of disease progression at the later, less frequent, dosing periods (i.e., every 2 weeks and every 4 weeks).